Priority question for written answer P-000579/2022 to the Commission
Rule 138
Christine Anderson (ID), Nicolaus Fest (ID), Virginie Joron (ID)

Subject: Commission acquisition strategy for vaccine doses

Although the EU only has 447 million inhabitants\(^1\), the Commission has acquired between 4.2 billion\(^2\) and 4.6 billion\(^3\) vaccine doses. Furthermore, it has failed to be fully transparent about the contracts that it has concluded, and, unsurprisingly, its president has also deleted some of her correspondence with the CEO of one major manufacturer from her phone.

While the EU has pledged 700 million vaccine doses to support poorer non-EU countries\(^4\), this does not explain why 3.9 billion vaccine doses, a rather enormous quantity, have been earmarked for use in the EU. Taking into account the size of the population of the EU, this means that the Commission has secured just under nine vaccine doses for every single person residing in the EU.

1. Can the Commission confirm that when concluding contracts with manufacturers, it operated on the assumption that no EU resident would need more than one or two doses to achieve complete immunisation? If so, what are its reasons for securing this large an oversupply at such a significant cost?
2. When is the deadline by which the manufacturers must deliver these vaccines?
3. Can the Commission specify the latest date by which all the vaccines it has ordered must be used, in order to prevent expired vaccine doses having to be disposed of?

Supporter\(^5\)

---

\(^1\) https://de.statista.com/statistik/daten/studie/14035/umfrage/europaeische-union-bevoelkerung-einwohner/
\(^3\) https://www.bundesregierung.de/breg-de/themen/europa/genug-impfstoff-eu-1985336
\(^4\) https://ec.europa.eu/commission/presscorner/detail/en/mex_21_6430
\(^5\) This question is supported by a Member other than the authors: Annika Bruna (ID)